Linagliptina/Metformina Sandoz

Linagliptin, the active ingredient in Linagliptina/Metformina Sandoz, is a DPP‑4 inhibitor presented as a tablet for oral use. It is combined with metformin hydrochloride, a biguanide, to treat type 2 diabetes mellitus in adults. GNH USA supplies Linagliptina/Metformina Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptina/Metformina Sandoz is indicated for the management of type 2 diabetes mellitus, acting on glucose regulation pathways.

- Type 2 diabetes mellitus (monotherapy): improves glycemic control when diet and exercise are insufficient. - Type 2 diabetes mellitus (combination therapy): used together with other antidiabetic agents to achieve target HbA1c levels. - Adjunct to lifestyle modification: supports blood‑glucose reduction alongside diet and physical activity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, usually transient. - Headache: mild tension‑type headaches. - Upper respiratory tract infection: nasopharyngitis symptoms. - Dizziness: occasional light‑headedness. - Abdominal discomfort: mild cramping or bloating.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe hypoglycemia: especially when combined with insulin or sulfonylureas. - Hepatic failure: marked liver enzyme elevation. - Allergic reactions: rash, angioedema, or anaphylaxis. - Renal impairment: worsening kidney function requiring discontinuation.

Before initiating therapy, assess renal and hepatic function and consider patient‑specific risk factors.

- Renal function assessment: evaluate eGFR; avoid in severe renal impairment. - Hepatic function monitoring: check liver enzymes periodically. - Lactic acidosis risk: discontinue if signs of metabolic acidosis appear. - Pregnancy and lactation: safety not established; use only if benefits outweigh risks. - Hypoglycemia monitoring: especially when combined with insulin or sulfonylureas. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Linagliptina/Metformina Sandoz may interact with several drug classes; review patient medication lists.

Major Interactions (Avoid): - Iodinated contrast agents: increase risk of metformin‑associated lactic acidosis. - Severe renal impairment drugs: contraindicated with other nephrotoxic agents. - Cimetidine: may raise metformin plasma concentrations. - Strong CYP3A4 inhibitors: can elevate linagliptin levels. - Alcohol excess: potentiates metformin‑related lactic acidosis.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal clearance of metformin. - Beta‑blockers: can mask hypoglycemia symptoms. - ACE inhibitors: monitor blood pressure and renal function. - NSAIDs: may impair renal function, increasing metformin exposure. - Rifampicin: may reduce linagliptin efficacy.